By Dr. SkinnyVIP · Published October 23, 2026 · Every quote links to Mass General Brigham's own statement or plan page
Mass General Brigham employee plans: GLP-1s for weight loss (Wegovy, Zepbound, Saxenda and other obesity drugs) are no longer covered starting January 1, 2027; existing approvals end December 31, 2026. Diabetes coverage continues, and an HRA offers some financial help.
Mass General Brigham Health Plan (commercial): weight-management GLP-1 coverage ended in 2026 (January 1 for individual and small groups, at renewal for large groups) unless a 50+ subscriber employer added it back.
Mass General Brigham ACO (MassHealth): weight-loss-only coverage ended July 2026; Wegovy can still be covered for sleep apnea, certain liver conditions, or prior heart attack, stroke or peripheral artery disease.
"Mass General Brigham" covers three different groups of people with three different GLP-1 rules. Find your row first; everything below depends on it.
| Who you are | Weight-loss coverage ends | What is still covered | Source |
|---|---|---|---|
| Mass General Brigham employee medical plans | January 1, 2027 (approvals end Dec 31, 2026) | Diabetes GLP-1s, subject to criteria; HRA financial assistance | MGB statement via On The Pen |
| Mass General Brigham Health Plan, fully insured commercial | January 1, 2026 (individual and small group); 2026 renewal (large group) | Type 2 diabetes GLP-1s (Ozempic, Mounjaro, Trulicity) with prior auth; 50+ subscriber employers may add weight-management coverage | MGB Health Plan |
| Mass General Brigham ACO (MassHealth members) | July 2026 | Wegovy for moderate to severe sleep apnea, certain liver conditions, or prior heart attack, stroke or symptomatic PAD; diabetes drugs by new prescription | MGB ACO |
“Beginning January 1, 2027, GLP-1 medications prescribed for weight loss will no longer be covered through the pharmacy benefit of affected Mass General Brigham employee medical plans.”
“Coverage for GLP-1 medications prescribed for diabetes will continue, subject to plan coverage criteria.”
“We will continue providing financial assistance for eligible employees and covered family members through a Health Reimbursement Arrangement, with greater assistance for employees at lower wage levels.”
According to On The Pen, a CVS Caremark letter to members dated October 12, 2026 says existing prior authorizations for weight-management medications expire on December 31, 2026, and the change applies to Wegovy, Zepbound and Saxenda as well as other obesity medications. MGB did not publish how many employees and family members are affected or the HRA dollar amount.
“While we are continuing to cover GLP-1s for type 2 diabetes, we no longer provide coverage of GLP-1 medications for weight management.”
“This coverage change was effective on January 1, 2026, for individual and small groups and upon renewal in 2026 for large groups.”
“Employer accounts with 50 or more enrolled subscribers will have the option to add coverage of GLP-1s for weight management when their plans renew in 2026.”
If your employer buys its insurance from the MGB Health Plan, the one question for HR is whether the company elected that add-back. It is a yes-or-no answer.
“Beginning July 3, 2026, weight loss medications will no longer be covered unless approved by your Mass General Brigham ACO plan, based on information provided by your doctor that shows a medical reason for use other than weight loss alone.”
The ACO lists the conditions that may still qualify for Wegovy: moderate to severe obstructive sleep apnea, certain liver conditions, and a history of heart attack, stroke or symptomatic peripheral artery disease. If you have diabetes or prediabetes, your clinician needs to write a new prescription for a diabetes drug. This follows the statewide MassHealth change; see MassHealth ended GLP-1 coverage for weight loss.
1. Fill what is already approved. If you have an active prior authorization, any refill before December 31 is still covered under the current rules.
2. Ask your clinician about a covered diagnosis. Type 2 diabetes remains covered on every MGB plan. If you also have sleep apnea, a liver condition, or cardiovascular history, ask whether a request under that indication is appropriate. A covered diagnosis is not a workaround; it is a different, documented medical reason.
3. Get the HRA details in writing. Ask Health Pros or HR three things: the annual amount, whether it reimburses cash-pay prescriptions (including compounded medications), and whether it starts January 1.
4. Do the cash-pay math before January. LillyDirect self-pay Zepbound runs $299 to $699 a month by dose (see our Real-Price Index). Medicare Part D members may qualify for the $50 Medicare GLP-1 Bridge. Compounded tirzepatide from licensed telehealth programs typically runs $200 to $350 a month.
5. Do not stop and restart at a high dose. If you will have a gap in January, tell whichever clinician prescribes next; after a break of more than two weeks, the dose usually needs to step back down. See our dosing reference.
SkinnyVIP is a Florida-based, physician-founded telehealth practice serving Massachusetts patients. Clinician-prescribed compounded tirzepatide is $695 for a 3-month plan (about $232 a month) or $350 for a single month, the same price at every dose, with no membership fee, no subscription and no automatic renewal; we do not store your card, so a refill happens only when you ask. If a licensed clinician does not prescribe, the medication cost is refunded in full. A person, never a bot, answers within one hour, 7 days a week, 9am to 9pm ET.
Compounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review them for safety, effectiveness or quality before marketing; compounded tirzepatide is a separate product from FDA-approved Zepbound® and Mounjaro®. Individual results vary. If your HRA reimburses prescriptions, we provide itemized receipts.
Related: Blue Cross Blue Shield of Massachusetts dropped GLP-1 weight-loss coverage in 2026 · Employers dropping GLP-1 coverage for 2027 · All coverage changes we track
Not for affected Mass General Brigham employee medical plans. MGB states that beginning January 1, 2027, GLP-1 medications prescribed for weight loss will no longer be covered through the pharmacy benefit of those plans. The Mass General Brigham Health Plan and the MGB ACO stopped covering weight-loss-only GLP-1s in 2026.
December 31, 2026, according to a CVS Caremark letter to members dated October 12, 2026, as reported by On The Pen. Fill any remaining approved prescription before then.
No. MGB says coverage for GLP-1 medications prescribed for diabetes will continue, subject to plan coverage criteria. The MGB Health Plan likewise says coverage for type 2 diabetes GLP-1s such as Ozempic and Mounjaro is not changing, with prior authorization still required.
MGB says it will continue providing financial assistance to eligible employees and covered family members through a Health Reimbursement Arrangement, with greater assistance at lower wage levels. The dollar amount and eligible expenses were not published; ask Health Pros or HR in writing whether the HRA can pay for a cash-pay or compounded prescription.
Ask your clinician whether you qualify under a covered indication rather than weight loss alone: type 2 diabetes for all MGB plans, and for MGB ACO members, Wegovy may be covered for moderate to severe obstructive sleep apnea, certain liver conditions, or a history of heart attack, stroke or symptomatic peripheral artery disease. Your clinician submits the request with the supporting documentation.
For fully insured commercial members, the Health Plan states it no longer covers GLP-1 medications for weight management; the change took effect January 1, 2026 for individual and small groups and on 2026 renewal for large groups. Employers with 50 or more enrolled subscribers can choose to add weight-management coverage at renewal.
LillyDirect sells Zepbound to self-pay patients at published prices by dose; Medicare Part D members may qualify for the $50 Medicare GLP-1 Bridge; and clinician-prescribed compounded tirzepatide at SkinnyVIP is $695 for a 3-month plan (about $232 a month) or $350 for one month, the same at every dose, with no membership and nothing that renews. Compounded medications are not FDA-approved products; a licensed clinician decides whether to prescribe, and prescription is not guaranteed.
Fill what is approved, ask about covered diagnoses and the HRA, then compare. SkinnyVIP: $695 for 3 months (about $232/month) or $350 for one, any dose, nothing renews.
Start your consultationCompounded tirzepatide is prepared by licensed compounding pharmacies under physician supervision. Compounded medications are not FDA-approved products, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Compounded tirzepatide is separate from FDA-approved Mounjaro® and Zepbound®. A licensed clinician reviews every request; prescription is not guaranteed. Individual results vary. Not affiliated with Novo Nordisk (Ozempic®/Wegovy®) or Eli Lilly (Mounjaro®/Zepbound®). This page is general information about published coverage policies, not insurance, legal or medical advice; confirm details with your plan.